Mutual of America Capital Management LLC Sells 831 Shares of LivaNova PLC $LIVN

Mutual of America Capital Management LLC lessened its holdings in LivaNova PLC (NASDAQ:LIVN) by 3.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,116 shares of the company’s stock after selling 831 shares during the quarter. Mutual of America Capital Management LLC’s holdings in LivaNova were worth $1,221,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in LivaNova by 182.5% in the 2nd quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock valued at $28,000 after buying an additional 407 shares during the period. CWM LLC lifted its holdings in shares of LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company’s stock valued at $34,000 after acquiring an additional 299 shares during the period. Parallel Advisors LLC lifted its holdings in shares of LivaNova by 1,312.3% during the second quarter. Parallel Advisors LLC now owns 1,031 shares of the company’s stock valued at $46,000 after acquiring an additional 958 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of LivaNova by 415.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company’s stock valued at $58,000 after acquiring an additional 1,184 shares during the period. Finally, Strs Ohio bought a new position in shares of LivaNova during the first quarter valued at $130,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Performance

Shares of LIVN stock opened at $54.89 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. The stock has a market cap of $3.00 billion, a PE ratio of -14.11 and a beta of 0.95. The stock has a 50-day moving average of $54.53 and a 200-day moving average of $47.12. LivaNova PLC has a one year low of $32.48 and a one year high of $58.91.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.21. The company had revenue of $352.50 million during the quarter, compared to analysts’ expectations of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.LivaNova’s revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.93 EPS. As a group, sell-side analysts expect that LivaNova PLC will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on LIVN shares. Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of LivaNova in a report on Wednesday, September 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of LivaNova in a research note on Saturday. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. The Goldman Sachs Group set a $55.00 price target on LivaNova and gave the company a “neutral” rating in a report on Wednesday, October 1st. Finally, Barclays lifted their price target on LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $59.71.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.